{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:07:44Z","timestamp":1789592864075,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-023-02585-w","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T19:01:44Z","timestamp":1686250904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inhaled Adjunct Therapy with Second-Line Drug Candidates for Dose Reduction in Chemotherapeutic Regimens for Multi-drug-Resistant Tuberculosis"],"prefix":"10.1208","volume":"24","author":[{"given":"Sonia","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils-Jorgen K.","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. V.","family":"Siva Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasham Shafi","family":"Sofi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Azmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipika","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav N.","family":"Mugale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotsna","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-0694","authenticated-orcid":false,"given":"Amit","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2585_CR1","first-page":"68","volume-title":"Global Tuberculosis Report 202","author":"Anonymous","year":"2022","unstructured":"Anonymous. Global Tuberculosis Report 202. Geneva: World Health Organization; 2022. p. 68."},{"issue":"10","key":"2585_CR2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. NEJM. 2020;382(10):893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814.","journal-title":"NEJM"},{"key":"2585_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ. Pretomanid: first approval. Drugs. 2019;79:1797\u2013803.","journal-title":"Drugs"},{"issue":"14","key":"2585_CR4","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/molecules26144280","volume":"26","author":"C Foti","year":"2021","unstructured":"Foti C, Piperno A, Giuffr\u00e8 O. Oxazolidinone antibiotics: chemical, biological and analytical aspects. Molecules (Basel, Switzerland). 2021;26(14):4280. https:\/\/doi.org\/10.3390\/molecules26144280.","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"16","key":"2585_CR5","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. NEJM. 2012;367(16):1508\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1201964.","journal-title":"NEJM"},{"key":"2585_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","volume":"20","author":"GS Shetye","year":"2020","unstructured":"Shetye GS, Franzblau SG, Cho S. New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. Transl Res. 2020;20:68\u201397.","journal-title":"Transl Res"},{"issue":"6","key":"2585_CR7","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1128\/aac.01920-13","volume":"58","author":"T Zhu","year":"2014","unstructured":"Zhu T, Friedrich SO, Diacon A, Wallis RS. Population pharmacokinetic\/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2014;58(6):3306\u201311. https:\/\/doi.org\/10.1128\/aac.01920-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2585_CR8","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/S2214-109X(15)00285-5","volume":"4","author":"J Andrews","year":"2016","unstructured":"Andrews J. To be or not to be exclusive: the sutezolid story. Lancet Glob Health. 2016;4(2):e89\u201390. https:\/\/doi.org\/10.1016\/S2214-109X(15)00285-5.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"2585_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4161\/cib.2.3.7926","volume":"2","author":"U Manjunatha","year":"2009","unstructured":"Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol. 2009;2(3):215\u20138.","journal-title":"Commun Integr Biol"},{"issue":"23","key":"2585_CR10","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1021\/jm101288t","volume":"53","author":"I Kmentova","year":"2010","unstructured":"Kmentova I, Sutherland HS, Palmer BD, Blaser A, Franzblau SG, Wan B, et al. Synthesis and structure\u2212 activity relationships of aza-and diazabiphenyl analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl] oxy}-6, 7-dihydro-5 H-imidazo [2, 1-b][1, 3] oxazine (PA-824). J Med Chem. 2010;53(23):8421\u201339.","journal-title":"J Med Chem"},{"issue":"1","key":"2585_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1128\/AAC.03823-14","volume":"59","author":"A Upton","year":"2015","unstructured":"Upton A, Cho S, Yang T, Kim Y, Wang Y, Lu Y, et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59(1):136\u201344.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6789","key":"2585_CR12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"CK Stover","year":"2000","unstructured":"Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962\u20136. https:\/\/doi.org\/10.1038\/35016103.","journal-title":"Nature"},{"issue":"6","key":"2585_CR13","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1128\/aac.49.6.2289-2293.2005","volume":"49","author":"S Tyagi","year":"2005","unstructured":"Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2005;49(6):2289\u201393. https:\/\/doi.org\/10.1128\/aac.49.6.2289-2293.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2585_CR14","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1080\/00498254.2017.1375168","volume":"48","author":"S Ntshangase","year":"2018","unstructured":"Ntshangase S, Shobo A, Kruger HG, Asperger A, Niemeyer D, Arvidsson PI, et al. The downfall of TBA-354 - a possible explanation for its neurotoxicity via mass spectrometric imaging. Xenobiotica. 2018;48(9):938\u201344. https:\/\/doi.org\/10.1080\/00498254.2017.1375168.","journal-title":"Xenobiotica"},{"issue":"2","key":"2585_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejps.2007.06.006","volume":"32","author":"P Muttil","year":"2007","unstructured":"Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32(2):140\u201350. https:\/\/doi.org\/10.1016\/j.ejps.2007.06.006.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"2585_CR16","doi-asserted-by":"publisher","first-page":"e00099","DOI":"10.1128\/aac.00099-19","volume":"63","author":"R Ranjan","year":"2019","unstructured":"Ranjan R, Srivastava A, Bharti R, Roy T, Verma S, Ray L, et al. Preclinical development of inhalable d-cycloserine and ethionamide to overcome pharmacokinetic interaction and enhance efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019;63(6):e00099-e119. https:\/\/doi.org\/10.1128\/aac.00099-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2585_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1128\/aac.01897-12","volume":"57","author":"RK Verma","year":"2013","unstructured":"Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother. 2013;57(2):1050\u20132. https:\/\/doi.org\/10.1128\/aac.01897-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2585_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","volume":"11","author":"KN Olivier","year":"2014","unstructured":"Olivier KN, Shaw PA, Glaser TS, Bhattacharyya D, Fleshner M, Brewer CC, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014;11(1):30\u20135. https:\/\/doi.org\/10.1513\/AnnalsATS.201307-231OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"2585_CR19","doi-asserted-by":"publisher","first-page":"e0149768","DOI":"10.1371\/journal.pone.0149768","volume":"11","author":"M Hoppentocht","year":"2016","unstructured":"Hoppentocht M, Akkerman OW, Hagedoorn P, Alffenaar JW, van der Werf TS, Kerstjens HA, et al. Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. PloS one. 2016;11(3):e0149768. https:\/\/doi.org\/10.1371\/journal.pone.0149768.","journal-title":"PloS one"},{"issue":"6","key":"2585_CR20","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1128\/aac.02346-12","volume":"57","author":"AS Dharmadhikari","year":"2013","unstructured":"Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2613\u20139. https:\/\/doi.org\/10.1128\/aac.02346-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2585_CR21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1021\/jm950956y","volume":"39","author":"MR Barbachyn","year":"1996","unstructured":"Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem. 1996;39(3):680\u20135.","journal-title":"J Med Chem"},{"issue":"6","key":"2585_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/02652040110055261","volume":"18","author":"RS Raghuvanshi","year":"2001","unstructured":"Raghuvanshi RS, Misra A, Talwar GP, Levy RJ, Labhasetwar V. Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid. J Microencaps. 2001;18(6):723\u201332. https:\/\/doi.org\/10.1080\/02652040110055261.","journal-title":"J Microencaps"},{"issue":"1","key":"2585_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejps.2008.02.008","volume":"34","author":"J Kaur","year":"2008","unstructured":"Kaur J, Muttil P, Verma RK, Kumar K, Yadav AB, Sharma R, et al. A hand-held apparatus for \u201cnose-only\u201d exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci. 2008;34(1):56\u201365. https:\/\/doi.org\/10.1016\/j.ejps.2008.02.008.","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"2585_CR24","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s11095-016-1926-0","volume":"33","author":"A Gupta","year":"2016","unstructured":"Gupta A, Sharma D, Meena J, Pandya S, Sachan M, Kumar S, et al. Preparation and preclinical evaluation of inhalable particles containing rapamycin and anti-tuberculosis agents for induction of autophagy. Pharm Res. 2016;33(8):1899\u2013912.","journal-title":"Pharm Res"},{"key":"2585_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174479","volume":"910","author":"S Gairola","year":"2021","unstructured":"Gairola S, Ram C, Syed AM, Doye P, Kulhari U, Mugale MN, et al. Nootkatone confers antifibrotic effect by regulating the TGF-\u03b2\/SMAD signaling pathway in mouse model of unilateral ureteral obstruction. Eur J Pharmacol. 2021;910: 174479.","journal-title":"Eur J Pharmacol"},{"key":"2585_CR26","doi-asserted-by":"publisher","first-page":"102198","DOI":"10.1016\/j.tube.2022.102198","volume":"134","author":"R Bharti","year":"2022","unstructured":"Bharti R, Roy T, Verma S, Reddy DVS, Shafi H, Verma K, et al. Transient, inhaled gene therapy with gamma interferon mitigates pathology induced by host response in a mouse model of tuberculosis. Tuberculosis (Edinb). 2022;134:102198. https:\/\/doi.org\/10.1016\/j.tube.2022.102198.","journal-title":"Tuberculosis (Edinb)."},{"key":"2585_CR27","doi-asserted-by":"publisher","first-page":"102081","DOI":"10.1016\/j.tube.2021.102081","volume":"128","author":"AK Singh","year":"2021","unstructured":"Singh AK, Verma RK, Mukker JK, Yadav AB, Muttil P, Sharma R, et al. Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month. Tuberculosis (Edinb). 2021;128:102081. https:\/\/doi.org\/10.1016\/j.tube.2021.102081.","journal-title":"Tuberculosis (Edinb)."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-023-02585-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-023-02585-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-023-02585-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T23:07:17Z","timestamp":1687475237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-023-02585-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["2585"],"URL":"https:\/\/doi.org\/10.1208\/s12249-023-02585-w","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"130"}}